Nasdaq

Assembly Biosciences Reports Promising Interim Results for ABI-4334 in Phase 1b Study for Chronic Hepatitis B Virus Infection

ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Morningstar

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral ...

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...
Seeking Alpha

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will ...
FOX40 News

Antiva Biosciences Announces Positive Top-Line Results from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk Human Papillomavirus (hrHPV) Infection

Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...
Morningstar

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...